Chonluten is a Khavinson peptide bioregulator — the synthetic tripeptide Glu-Asp-Gly ("EDG"), targeted at bronchopulmonary/respiratory tissue (also called Bronchogen).
Khavinson peptide bioregulator; synthetic tripeptide Glu-Asp-Gly (EDG), respiratory-targeted. Single compound.
Chonluten is a Khavinson short peptide bioregulator proposed to act through direct interaction with promoter-region DNA to modulate tissue-specific gene expression at low concentrations. In respiratory tissue it is described as regulating stress-response genes (c-Fos, HSP70), antioxidant enzymes (SOD), and inflammatory mediators (COX-2, TNF-alpha), restoring normal expression patterns in bronchial epithelium.
The few indexed documents are on-topic Khavinson-family papers (ultrashort-peptide regulation; peptides considered in the COVID-19 context). Chonluten has been studied for bronchial and pulmonary cell biology and age-associated respiratory-tract function.
Epistemic caveat: the literature comes essentially from Khavinson's St. Petersburg Institute of Bioregulation and Gerontology and Russian academic journals (for example, the Bulletin of Experimental Biology and Medicine) — a single group, working in preclinical and gerontology models, with no controlled human trials and little independent replication.
No human clinical trial has established administration parameters for Chonluten; VialTalk does not provide community-sourced dosing.
Not approved in any major jurisdiction; sold research-use-only. Reported as well tolerated in the originating literature; no independent safety dataset.
The compound is mechanistically interesting but evidentiarily weak from an independent standpoint: single-group, preclinical, with no controlled human trials.
Chonluten = EDG tripeptide (Glu-Asp-Gly), a lung/bronchial Khavinson bioregulator (also called Bronchogen). Same family as Thymogen, Ovagen, Prostamax, and Epitalon.
